These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16424787)

  • 1. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization.
    Gómez-Hernández A; Sánchez-Galán E; Martín-Ventura JL; Vidal C; Blanco-Colio LM; Ortego M; Vega M; Serrano J; Ortega L; Hernández G; Tunón J; Egido J
    J Cardiovasc Pharmacol; 2006 Jan; 47(1):60-9. PubMed ID: 16424787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB.
    Gómez-Hernández A; Martín-Ventura JL; Sánchez-Galán E; Vidal C; Ortego M; Blanco-Colio LM; Ortega L; Tuñón J; Egido J
    Atherosclerosis; 2006 Jul; 187(1):139-49. PubMed ID: 16212965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin.
    Muñoz-García B; Martín-Ventura JL; Martínez E; Sánchez S; Hernández G; Ortega L; Ortiz A; Egido J; Blanco-Colio LM
    Stroke; 2006 Aug; 37(8):2044-53. PubMed ID: 16809572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability.
    Massaro M; Zampolli A; Scoditti E; Carluccio MA; Storelli C; Distante A; De Caterina R
    Cardiovasc Res; 2010 May; 86(2):311-20. PubMed ID: 19946014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques.
    Durán MC; Martín-Ventura JL; Mohammed S; Barderas MG; Blanco-Colio LM; Mas S; Moral V; Ortega L; Tuñón J; Jensen ON; Vivanco F; Egido J
    Eur J Pharmacol; 2007 May; 562(1-2):119-29. PubMed ID: 17336287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans.
    Cipollone F; Fazia M; Iezzi A; Zucchelli M; Pini B; De Cesare D; Ucchino S; Spigonardo F; Bajocchi G; Bei R; Muraro R; Artese L; Piattelli A; Chiarelli F; Cuccurullo F; Mezzetti A
    Circulation; 2003 Mar; 107(11):1479-85. PubMed ID: 12654603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells.
    Wagner AH; Gebauer M; Güldenzoph B; Hecker M
    Arterioscler Thromb Vasc Biol; 2002 Nov; 22(11):1784-9. PubMed ID: 12426205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human.
    Cipollone F; Fazia ML; Iezzi A; Cuccurullo C; De Cesare D; Ucchino S; Spigonardo F; Marchetti A; Buttitta F; Paloscia L; Mascellanti M; Cuccurullo F; Mezzetti A
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1925-31. PubMed ID: 16020747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month.
    Martín-Ventura JL; Blanco-Colio LM; Gómez-Hernández A; Muñoz-García B; Vega M; Serrano J; Ortega L; Hernández G; Tuñón J; Egido J
    Stroke; 2005 Aug; 36(8):1796-800. PubMed ID: 16020773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity.
    Cipollone F; Fazia M; Iezzi A; Pini B; Cuccurullo C; Zucchelli M; de Cesare D; Ucchino S; Spigonardo F; De Luca M; Muraro R; Bei R; Bucci M; Cuccurullo F; Mezzetti A
    Circulation; 2004 Mar; 109(12):1482-8. PubMed ID: 15037537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [COX-2 and mPGES-1 expression in carotid atherosclerotic plaques].
    Liu HF; Li XH; Yang QD; Miao W; Qi SS; Song XM; He GS; Dong HL; Zhang FQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):453-6. PubMed ID: 17680542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation.
    Blanco-Colio LM; Villa A; Ortego M; Hernández-Presa MA; Pascual A; Plaza JJ; Egido J
    Atherosclerosis; 2002 Mar; 161(1):17-26. PubMed ID: 11882313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.
    Hernández-Presa MA; Martín-Ventura JL; Ortego M; Gómez-Hernández A; Tuñón J; Hernández-Vargas P; Blanco-Colio LM; Mas S; Aparicio C; Ortega L; Vivanco F; Gerique JG; Díaz C; Hernández G; Egido J
    Atherosclerosis; 2002 Jan; 160(1):49-58. PubMed ID: 11755922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin.
    Li M; Liu Y; Dutt P; Fanburg BL; Toksoz D
    Am J Physiol Lung Cell Mol Physiol; 2007 Aug; 293(2):L463-71. PubMed ID: 17545489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury.
    Mason JC; Ahmed Z; Mankoff R; Lidington EA; Ahmad S; Bhatia V; Kinderlerer A; Randi AM; Haskard DO
    Circ Res; 2002 Oct; 91(8):696-703. PubMed ID: 12386146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.
    Ortego M; Bustos C; Hernández-Presa MA; Tuñón J; Díaz C; Hernández G; Egido J
    Atherosclerosis; 1999 Dec; 147(2):253-61. PubMed ID: 10559511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
    Verhoeven BA; Moll FL; Koekkoek JA; van der Wal AC; de Kleijn DP; de Vries JP; Verheijen JH; Velema E; Busser E; Schoneveld A; Virmani R; Pasterkamp G
    Stroke; 2006 Aug; 37(8):2054-60. PubMed ID: 16809559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.
    Cipollone F; Iezzi A; Fazia M; Zucchelli M; Pini B; Cuccurullo C; De Cesare D; De Blasis G; Muraro R; Bei R; Chiarelli F; Schmidt AM; Cuccurullo F; Mezzetti A
    Circulation; 2003 Sep; 108(9):1070-7. PubMed ID: 12912808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an in vivo and in vitro study.
    Dolkart O; Liron T; Chechik O; Somjen D; Brosh T; Maman E; Gabet Y
    Am J Sports Med; 2014 Dec; 42(12):2869-76. PubMed ID: 25184246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological modulation of plaque instability.
    Mezzetti A
    Lupus; 2005; 14(9):769-72. PubMed ID: 16218485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.